Form 4: Shattuck Labs Chief Technical Officer Reports Stock Transactions

Abhinav A. Shukla, Chief Technical Officer of Shattuck Labs, reports the acquisition of stock options and the disposal of shares to cover tax obligations.

Summary

• Abhinav A. Shukla, the Chief Technical Officer of Shattuck Labs, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On January 25, 2025, Mr. Shukla disposed of 2,261 shares of common stock at a price of $1.16 per share to cover tax obligations.
• Following this transaction, Mr. Shukla beneficially owns 73,536 shares of common stock.
• On January 28, 2025, Mr. Shukla was granted an option to purchase 165,200 shares of common stock at an exercise price of $1.18 per share.
• The options vest over time, with one quarter vesting on January 28, 2026, and the remaining three quarters vesting in equal monthly installments through January 28, 2029, contingent on continued service.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and does not indicate any significant positive or negative sentiment. The stock option grant is a positive sign of alignment with the company's long-term goals.

Positives

• The grant of stock options to the Chief Technical Officer aligns his interests with the long-term success of the company.
• The vesting schedule of the options incentivizes continued service and commitment from Mr. Shukla.

Negatives

• The disposal of 2,261 shares, while for tax purposes, slightly reduces Mr. Shukla's direct shareholding.

Risks

• The value of the stock options is dependent on the future performance of Shattuck Labs' stock price.
• The vesting of the options is contingent on Mr. Shukla's continued employment with the company.

Future Outlook

The document does not contain any specific forward-looking statements about the company's future performance, but the vesting schedule of the options suggests a long-term commitment from the executive.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in publicly traded companies. It provides transparency into the stock ownership of key executives.

Comparison to Industry Standards

• Stock option grants and vesting schedules are standard practice in the biotechnology industry to attract and retain talent.
• The vesting schedule of the options is typical, with a portion vesting after one year and the remainder over a multi-year period.
• The exercise price of the options is close to the market price at the time of the grant, which is a common practice.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of shareholders.
• The disposal of shares for tax purposes has a minor impact on the overall shareholding.

Key Dates

Keywords

Shattuck Labs, Abhinav A. Shukla, stock options, Form 4, insider trading, share disposal, vesting, equity compensation